The Value of Circulating Tumor DNA in the Perioperative Setting in Pancreatic Cancer

The concept of looking for circulating tumor DNA in the perioperative setting and helping to decide which patients might need more therapy from there. How much has this been looked at in the setting of pancreatic cancer to potentially select or deselect the patients who might need adjuvant therapy versus the approach that your data show that really suggest that there's likely to be a value to adjuvant Therapy quite broadly.